Price list of bosutinib/bosutinib after inclusion in medical insurance

Bosutinib has not yet been officially launched in mainland China. Its original drug was developed by Pfizer of the United States and sold under the trade name "Bosulif" in many countries and regions. It is mainly used to treat chronic myeloid leukemia (CML), and has shown good efficacy especially in patients who are ineffective or intolerant to previous generations of TKI treatments. However, since it has not yet passed the formal registration approval by China's National Medical Products Administration (NMPA), the drug has not yet been included in the National Medical Insurance Drug List.

The fact that bosutinib is not on the market in China means that patients cannot obtain the drug through medical insurance channels, nor can they directly prescribe the drug in domestic hospital pharmacies. Currently, if patients in mainland China need to use bosutinib, they mainly rely on the following two methods: one is to purchase it through cross-border medical channels; the other is through overseas direct mail platforms. However, there are compliance and safety issues in this method, so special caution is required.

Since it is not included in medical insurance and there is no unified domestic pricing system, there is currently no clear "bosutinib price list" in the domestic market. Abroad, bosutinib is relatively expensive. For example, in the U.S. market, the monthly treatment cost of bosutinib can be as high as several thousand dollars. This is related to factors such as its being an original targeted drug, high research and development costs, and a small patient base.

Domestic patients may enjoy a certain price discount if they use bosutinib through cross-border medical channels, and overseas drugs will be directly introduced by licensed medical institutions. However, even so, the price is still high and the proportion of out-of-pocket expenses is high, which puts many patients under great pressure on their financial affordability.

Reference materials:https://go.drugbank.com/drugs/DB06616